viewImugene Ltd

Imugene Limited releases new clinical data for HER-Vaxx cancer vaccine study

Imugene Limited (ASX:IMU) chief executive officer Leslie Chong updates Proactive Investors on new clinical data from the Phase 1b study of its HER-Vaxx cancer vaccine after presenting at the European Society for Medical Oncology World Congress on gastrointestinal cancer in Spain over the weekend.

The data shows the cancer fighting antibody and clinical response rates continue to be positive in patients receiving the optimal biological dose of the vaccine.

Imugene’s HER-Vax is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER-2/neu receptor such as gastric, breast, ovarian, lung and pancreatic cancers.

Chong said the latest presentation for the vaccine further reinforced ongoing interest among the international oncology community in Imugene’s potentially revolutionary B-cell platform cancer vaccine and clinical development.

Quick facts: Imugene Ltd

Price: 0.058 AUD

Market: ASX
Market Cap: $256.71 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...



Imugene gets green light to start phase-1 clinical trial of new cancer...

Imugene Ltd's (ASX:IMU) Leslie Chong speaks to Proactive's Andrew Scott following the news it's received a second Human Research Ethics Committee approval to begin a phase-I clinical trial of its cancer checkpoint immunotherapy candidate, PD1-Vaxx. Ethics approval is confirmation that Imugene...

3 weeks ago

2 min read